健保血脂藥 給付門檻放寬

[newshine]

健保血脂藥 給付門檻放寬

點值會低
真的是有原因的
拼命請客

[smallant]

[施肇榮]

健保血脂藥 給付門檻放寬

點值會低
真的是有原因的
拼命請客

相關醫學會配合廠商促銷的結果

3好 + 1好

[truelovecoco]

重點是黑箱核刪率
你開的多.點值低.反而被刪的多
不一定會賺
好人政府做.壞人醫師當

[李誠民]

"相關醫學會配合廠商促銷的結果"......??;;那為什麼FDA-tw不表示意見,放任(同在衛生署下)健保局方寬???
醫學會被何廠商促銷邀品,也不是自今天開始,台灣的Sympusium不都是配合廠商的活動?????

[amaranth]

費用部分先不提,
學術上來說這個新標準只不過是跟上2004年的ATP3修正版而已,
新聞還講的好像是很新的國際建議....

[李誠民]

""newshine 寫:

健保血脂藥 給付門檻放寬

點值會低
真的是有原因的
拼命請客


相關醫學會配合廠商促銷的結果""
WEDNESDAY, July 24 (HealthDay News) -- Millions of Americans take statins to lower their stroke and heart attack risks, but new research from Taiwan suggests the drug may offer another health benefit: cutting the odds of developing Parkinson's disease.
...cholesterol levels reach the treatment goal.
This Taiwanese policy, set to end on Aug. 1, allowed researchers to evaluate any potential difference in Parkinson's risk in people who stopped statin use compared to those who continued taking the drug, Lin said. Parkinson's disease is a progressive neurological condition resulting in movement problems such as stiffness, tremors and slurred speech.
Prior research examining the link between statin use and Parkinson's disease showed inconsistent results. The new study, which took place from 2001 to 2008 on statin patients free of Parkinson's disease, also showed that participants taking water-soluble statins developed Parkinson's at about twice the rate as those taking fat-soluble statins.
Dr. Michael Okun, national medical director of the National Parkinson Foundation in Miami, said the findings were "intriguing有趣的 吸引人的 but not surprising" in light of recent interest in lipid-lowering drugs to reduce Parkinson's risk. But Okun said caution should be exercised in interpreting the study's results....
Taiwan's national health insurance program forces physicians to stop prescribing statins once the patient's cholesterol reaches the treatment goal. The policy allowed researchers to track what happens when people stop taking the medication, compared to those who stay on them. ........

Discontinuation of statin therapy associates with Parkinson disease: A population-based study
Lee, Yen-Chieh MD; Lin, Chin-Hsien MD, PhD; Wu, Ruey-Meei MD, PhD; Lin, Min-Shung MD; Lin, Jou-Wei MD, PhD; Chang, Chia-Hsuin MD, PhD; Lai, Mei-Shu PhD
Neurology
Issue: Volume 81(5), 30 July 2013, p 410–416
(
From the Department of Family Medicine (Y.-C.L., M.-S.L), Cathay General Hospital, Taipei; the Departments of Neurology (C.-H.L., R.-M.W.) and Medicine (C.-H.C.), National Taiwan University Hospital, Taipei; Department of Medicine, College of Medicine (J.-W.L., C.-H.C.), and Institute of Preventive Medicine, College of Public Health (C.-H.C., M.-S.L.), National Taiwan University, Taipei; and Cardiovascular Center (J.-W.L.), National Taiwan University Hospital Yun-Lin Branch, Dou-Liou City, Yun-Lin County, Taiwan)

[李誠民]

published in the Journal of the American College of Cardiology4, discovered that statin use led to dramatically reduced fitness benefits from exercise, in some cases actually making the volunteer LESS fit than before!

One group was given a daily 40 mg dose of simvastatin (Zocor). The other group did not receive any medication. Both groups then began a supervised 12-week exercise program, walking or jogging on a treadmill for 45 minutes, five days a week. At the end of the three-month long trial, their aerobic fitness and muscles were retested. The results were astounding:
• On average, unmedicated volunteers improved their aerobic fitness by more than 10 percent. Mitochondrial content activity increased by 13 percent
• Volunteers taking 40mg of simvastatin improved their fitness by a mere 1.5 percent on average, and some had reduced their aerobic capacity at the end of the 12-week fitness program. Mitochondrial content activity decreased by an average of 4.5 percent

“According to senior study author John P. Thyfault, a professor of nutrition and exercise physiology at the University of Missouri5:
“Low aerobic fitness is one of the best predictors of premature death. And if statins prevent people from raising their fitness through exercise, then that is a concern.”
……………
其次,statin 可能增加TypeIID.M.的機率…..
可能加速腎功能的衰退.…..
p.s.:現在有太多證據顯示::Statin是否太濫用了?!--美國45歲以上人,每四個就有一個使用Statin 藥物,;台灣前幾年Lipidor 使用一直是健保用藥前三名....!但基層使用卻被無明理由刪退,還要放大扣款......,到底Lipidor用到哪了?!...
茉莉花革命???........

[chenyuehchung.]

費用部分先不提,
學術上來說這個新標準只不過是跟上2004年的ATP3修正版而已,
新聞還講的好像是很新的國際建議....

+1
抄也抄不好,翻譯機翻的還比他準......

[amin30]

費用部分先不提,
學術上來說這個新標準只不過是跟上2004年的ATP3修正版而已,
新聞還講的好像是很新的國際建議....

+1

[Felix]

重點是黑箱核刪率
你開的多.點值低.反而被刪的多
不一定會賺
好人政府做.壞人醫師當

沒錯~~~
可民眾卻以為撿到便宜....."點值低,核刪放大"又不是虧到我......殊不知總額沒增加,卻一直開放高貴藥與檢查是會有"排擠效應"的